Ten orelabrutinib studies were selected for the 64th Annual Meeting of the American Society of Hematology (ASH).

On November 8, 2022, biomedical high-tech company InnoCare (HKEx: 09969; SSE: 688428) today announced that 10 studies of orelabrutinib, a Bruton tyrosine kinase (BTK) inhibitor, were selected for the 64th Annual Meeting
of the American Society of Hematology (ASH).
The ASH Annual Meeting will be held
online and in-person in New Orleans, USA on December 10-13, 2022.

Oral presentation

       ：Orelabrutinib, Rituximab, and High-Dose Methotrexate (HD-MTX) in Newly Diagnosed Primary Central Nervous System Lymphoma (PCNSL): A Retrospective Analysis on Efficacy, Safety, and Biomarker

Orelabrutinib, rituximab, and high-dose methotrexate (HD-MTX) in the treatment of treatment-new primary central nervous system lymphoma (PCNSL): a retrospective analysis of efficacy, safety, and biomarkers

Abstract Code: 558

Breakout Venue: 627.
Aggressive Lymphomas: Clinical and Epidemiological: Real World Evidence for Management of CNS Lymphoma and Post CAR T-cell relapse for aggressive B-cell NHL

627.
Aggressive lymphoma: clinical and epidemiology: real-world evidence from central nervous system lymphoma treatment and recurrence of aggressive B-cell non-Hodgkin lymphoma CAR-T cells

EST: Sunday, December 11, 2022 1:15 p.
m.
ET

First author: Zhao Shihua

Corresponding author: Huang Wenrong

Poster Presentation 1

       ：A Multicenter, Single-Arm, Prospective Phase II Study of Orelabrutinib Combined with High-Dose Methotrexate and Rituximab Sequential Autologous Hematopoietic Stem Cell Transplantation in Newly-Diagnosed Primary Central Nervous System Lymphoma

A multicenter, single-arm, prospective phase II study of orelabrutinib combined with high-dose methotrexate and rituximab sequential autologous hematopoietic stem cell transplantation in the treatment of primary central nervous system lymphoma

Abstract code: 1624

Breakout Venue: 626.
Aggressive Lymphomas: Prospective Therapeutic Trials: Poster I

626.
Invasive lymphoma: Prospective treatment trial: Poster I

EST: Saturday, December 10, 2022 from 5:30 p.
m.
to 7:30 p.
m.
ET

First author: Ma Ji

Poster Presentation 2

       ：Efficacy and Safety of Lenalidomide, Anti-PD-1 Antibody Combined with Orelabrutinib or Rituximab in the Treatment of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Efficacy and safety of lenalidomide, anti-PD-1 antibodies plus orelabrutinib or rituximab in the treatment of relapsed/refractory diffuse large B-cell lymphoma

Abstract code: 1636

Breakout Venue: 626.
Aggressive Lymphomas: Prospective Therapeutic Trials: Poster I

626.
Invasive lymphoma: Prospective treatment trial: Poster I

EST: Saturday, December 10, 2022 from 5:30 p.
m.
to 7:30 p.
m.
ET

First author: Miao Yuqing

Contact: Xu Hao

Poster Presentation 3

       ：Preliminary Result of Phase 1 Trial of Orelabrutinib in Combination with Rituximab, Methotrexate, and Dexamethasone in Patients with Newly Diagnosed Primary CNS Lymphoma Implementing Bayesian Design for Dose-Seeking

Preliminary results from a phase I trial of orelabrutinib combined with rituximab, methotrexate, and dexamethasone in Bayesian-designed doses to explore the treatment of primary central nervous system lymphoma

Abstract code: 2951

Breakout Venue: 626.
Aggressive Lymphomas: Prospective Therapeutic Trials: Poster II

626.
Aggressive lymphoma: A prospective treatment trial: Poster II

Sunday, December 11, 2022, 6 p.
m.
to 8 p.
m.
ET

First author: Yuan Yan

Corresponding author: Chen Tong

Poster presentation 4

       ：Thiotepa, Orelabrutinib, and Methotrexate Combined with or without the Rituximab Regimens in the Treatment of Patients with Central Nervous System Lymphoma

Setepep, orelabrutinib, and methotrexate with or without rituximab for central nervous system lymphoma

Abstract code: 4291

Breakout Venue: 627.
Aggressive Lymphomas: Clinical and Epidemiological: Poster III

627.
Invasive lymphoma: Clinical and epidemiology: poster III

Monday, December 12, 2022, 6 p.
m.
to 8 p.
m.
ET

First author: Zeng Ruolan

Contact: Zhou Hui

Poster Presentation 5

       ：Orelabrutinib in Combination with Rituximab and chemotherapy for Newly Diagnosed Aggressive B-Cell Lymphoma: A Multicenter, Single-Arm, Prospective Study

Orelabrutinib in combination with rituximab and chemotherapy for treatment-naïve aggressive B-cell lymphoma: a multicenter, single-arm, prospective study

Abstract code: 4295

Breakout Venue: 627.
Aggressive Lymphomas: Clinical and Epidemiological: Poster Ⅲ

627.
Invasive lymphoma: Clinical and epidemiology: poster III

Monday, December 12, 2022, 6 p.
m.
to 8 p.
m.
ET

First author: Zhou Xiangxiang

Corresponding author: Wang Xin

Publish online1

       ：A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study evaluating the Efficacy and Safety of Orelabrutinib Plus R-CHOP Versus Placebo Plus R-CHOP in Treatment-Naive Patients with Mcd Subtype Diffuse Large B-Cell Lymphoma

A phase III, randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy and safety of orelabrutinib plus R-CHOP versus placebo plus R-CHOP in treating new-treated MCD subtype diffuse large B-cell lymphoma

Abstract code: 5525

First author: Xu Pengpeng

Corresponding author: Zhao Weiyi

Publish 2 online

：A Phase I/II Study of Orelabrutinib Combined with Anti-Programmed Cell Death Protein-1 Antibody and Fotemustine for Patients with Newly Diagnosed Primary Central Nervous System Lymphoma ( PCNSL)

Phase I/II study of orelabrutinib combined with anti-PD-1 antibody and formostine in the treatment of primary central nervous system lymphoma

Abstract code: 5508

First author: Zhang Xudong

Corresponding author: Zhang Mingming

Publish online3

       ：Preliminary Outcomes of Orelabrutinib Plus RCHOP in Treatment-Na?ve Patients with Double-expression Diffuse Large B Cell Lymphoma

Initial efficacy of orelabrutinib combined with RCHOP in the treatment of naïve double-expression diffuse large B-cell lymphoma

Abstract code: 5521

First author: Yang Yang

Corresponding author: Cai Zhen

Publish online4

       ：Orelabrutinib and Venetoclax Show Synergistic Lethality in Double-Hit Lymphoma By Interfering with the Crosstalk between the PI3K/AKT and p38/MAPK Signaling

Orelabrutinib combined with venetoclax produce a synergistic lethal effect on double-blow lymphoma by interfering with the interaction of PI3K/AKT and p38/MAPK pathways

Abstract code: 5248

First author: Zhong Mengya

Contact: Xu Bing

About orelabrutinib

Orelabrutinib is a Class 1 new drug developed by InnoCare, which is a highly selective new BTK inhibitor for the treatment of hematological tumors and autoimmune diseases
.

Orelabrutinib was conditionally approved in China on December 25, 2020 for the treatment of relapsed/refractory chronic lymphoblastic leukemia (CLL)/small lymphocytic lymphoma (SLL) and relapsed/refractory mantle cell lymphoma (MCL).

At the end of 2021, orelabrutinib was included in the national health insurance to benefit more patients
.

The marketing applications for orelabrutinib for the treatment of relapsed/refractory Waldenstrom macroglobulinemia (WM) and relapsed/refractory treatment of marginal zone lymphoma (MZL) have been accepted
in China.

In addition, multi-center, multi-indication clinical trials with orelabrutinib as a single or combination drug are being conducted in China and the United States, such as the first-line treatment of diffuse large B-cell lymphoma (DLBCL) MCD subtype and other indications
.

Orelabrutinib has been granted Breakthrough Therapy Designation by the U.
S.
Food and Drug Administration (FDA) for the treatment of relapsed/refractory mantle cell lymphoma (R/R MCL).

A global Phase II clinical study of orelabrutinib for the treatment of multiple sclerosis (MS) and clinical trials in China for the treatment of systemic lupus erythematosus (SLE), primary immune thrombocytopenia (ITP) and neuromyelitis optica spectrum disease (NMOSD) are ongoing
.